Canakinumab (ACZ885) is a recombinant human monoclonal antibody that specifically targets and neutralizes interleukin-1 beta (IL-1??). Demonstrating potent inhibitory activity, canakinumab exhibits half-maximal inhibitory concentrations (IC50) of 43.6 pM for human IL-1?? and 40.8 pM for marmoset IL-1??. Its primary mechanism involves the interruption of IL-1?? signaling, effectively reducing inflammatory responses associated with autoimmune disorders. This antibody is pivotal for research focused on the pathophysiology and potential therapeutic interventions for inflammation-driven diseases.
Canakinumab (ACZ885) is a recombinant human monoclonal antibody that specifically targets and neutralizes interleukin-1 beta (IL-1??). Demonstrating potent inhibitory activity, canakinumab exhibits half-maximal inhibitory concentrations (IC50) of 43.6 pM for human IL-1?? and 40.8 pM for marmoset IL-1??. Its primary mechanism involves the interruption of IL-1?? signaling, effectively reducing inflammatory responses associated with autoimmune disorders. This antibody is pivotal for research focused on the pathophysiology and potential therapeutic interventions for inflammation-driven diseases.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
